Insulet AI Stock Analysis
Want to see PODD full AI Analyst Report?
Insulet (PODD) AI Stock Analysis
Insulet
(NASDAQ:PODD)
The score is driven primarily by strong profitability and margin expansion momentum reinforced by a positive earnings call and supportive 2026 guidance. Offsetting factors are the sharp recent decline in TTM cash flow and weak cash conversion, plus an overbought technical setup and a growth-leaning valuation without dividend support.
Insulet Key Performance Indicators (KPIs)
Revenue by SegmentProvides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Omnipod is the growth engine—U.S. and international sales have scaled rapidly, with international accelerating faster and taking a larger share while Drug Delivery remains negligible. Management confirmed international strength (raised guidance to ~30–32%) but trimmed U.S. outlook due to type‑2 onboarding/first‑90‑day retention issues and is rolling out customer‑care, sampling and sales fixes. Going forward, international execution will drive upside, but U.S. retention remediation (new customer starts, 90‑day utilization) is the key risk to watch.
Insulet (PODD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.71B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.57M
- Price to Earnings (P/E)
- 22.8
- Beta (1Y)
- 0.19
- Revenue Growth
- 26.46%
- EPS Growth
- 75.56%
- Country
- US
- Employees
- 5,400
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Insulet Business Overview & Revenue Model
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
How the Company Makes Money
Insulet primarily makes money by selling its Omnipod insulin delivery system through a recurring, disposable-based model. The largest revenue driver is the ongoing sale of Omnipod pods—single-use, wearable, tubeless insulin delivery devices that pati...
Insulet Earnings Call Summary
The call was strongly positive overall. Insulet reported nearly 20% third-quarter revenue growth, more than 20% customer-base growth, record gross margin, substantial operating-margin expansion, and 60% adjusted EPS growth. The company also raised its confidence in the high end of 2026 guidance, advanced multiple product and commercial initiatives, and announced increased share repurchase capacity. The main concerns were softer new customer starts, type 2 retention challenges, expected competitive share pressure, and a more conservative 2027 outlook with meaningful moderation in international growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Insulet expects constant currency revenue growth of 21% to 22% for total company and 21.5% to 22.5% for total Omnipod, with foreign exchange expected to positively contribute approximately a 100-basis-point to Omnipod and total company growth; US Omnipod revenue growth is expected at 17.5% to 18.5%, international Omnipod revenue growth at 32% to 33%, and fourth quarter total company, total Omnipod, US Omnipod, and international Omnipod revenue growth at 13.5% to 17%, 13% to 16.5%, 10% to 13.5%, and 21% to 24%, respectively, with foreign exchange expected to be a headwind of approximately 50 basis points to international growth. Insulet expects approximately 150 basis points of adjusted operating margin expansion, net interest and other expense of $40 million to $45 million, a non-GAAP tax rate of 20% to 20.5%, approximately 70 million shares outstanding, adjusted EPS growth of more than 30%, and free cash flow of approximately $275 million in 2026. For 2027, the company expects total company growth to be modestly below the mid teens framework, plans to guide toward the lower end of the prior 9% to 14% framework for the US, and expects international growth to moderate meaningfully from 2026; formal guidance is expected in February.
Insulet Financial Statement Overview
Summary
Strong profitability and margin profile (healthy net and EBIT margins) alongside meaningful leverage improvement support a solid fundamental base. However, the latest TTM cash-flow deterioration and weak cash conversion versus net income are a material risk, reducing overall financial consistency despite strong income-statement performance.
Income Statement
86Very PositiveBalance Sheet
74PositiveCash Flow
46Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19B | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B |
| Gross Profit | 2.29B | 1.94B | 1.45B | 1.16B | 805.60M | 752.10M |
| EBITDA | 686.30M | 509.60M | 423.70M | 323.60M | 109.00M | 139.60M |
| Net Income | 428.80M | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M |
Balance Sheet | ||||||
| Total Assets | 3.42B | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B |
| Cash, Cash Equivalents and Short-Term Investments | 584.40M | 716.10M | 953.40M | 704.20M | 674.70M | 791.60M |
| Total Debt | 962.10M | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B |
| Total Liabilities | 1.84B | 1.68B | 1.88B | 1.86B | 1.77B | 1.49B |
| Stockholders Equity | 1.58B | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M |
Cash Flow | ||||||
| Free Cash Flow | 260.00M | 377.70M | 305.40M | 70.10M | -38.30M | -190.80M |
| Operating Cash Flow | 509.00M | 569.30M | 430.30M | 145.70M | 119.00M | -68.10M |
| Investing Cash Flow | -284.80M | -222.70M | -146.20M | -119.40M | -191.10M | -82.70M |
| Financing Cash Flow | -394.40M | -595.30M | -28.10M | -13.60M | -40.30M | 40.70M |
Insulet Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 139.98 is below the 20-day moving average (MA) of 150.19, below the 50-day MA of 142.20, and below the 200-day MA of 171.04, indicating a bearish trend. The MACD of 0.65 indicates Positive momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 7.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.
Insulet Risk Analysis
Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksInsulet Peers Comparison
Overall Rating
MDT81Outperform
DXCM73Outperform
PODD70Outperform
ABT67Neutral
TNDM65Neutral
BBNX54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $130.88B | 24.69 | 10.60% | 2.84% | 9.77% | 12.28% | |
| 73Outperform | $30.78B | 31.86 | 36.50% | ― | 13.03% | 40.88% | |
| 70Outperform | $9.71B | 22.76 | 29.48% | ― | 26.46% | 75.56% | |
| 67Neutral | $181.35B | 38.70 | 9.11% | 2.41% | 10.00% | -66.06% | |
| 65Neutral | $1.19B | -23.72 | -35.61% | ― | 6.73% | 76.54% | |
| 54Neutral | $779.08M | -7.66 | -27.33% | ― | 43.69% | -3.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PODD | Insulet | 139.98 | -172.91 | -55.26% | |
| ABT | Abbott Laboratories | 104.48 | -16.48 | -13.63% | |
| DXCM | Dexcom | 82.52 | 24.10 | 41.25% | |
| MDT | Medtronic | 100.72 | 4.56 | 4.74% | |
| TNDM | Tandem Diabetes Care | 17.05 | -2.45 | -12.56% | |
| BBNX | Beta Bionics, Inc. | 14.33 | -14.07 | -49.54% |
Insulet Corporate Events
Insulet Reports Strong Third-Quarter Growth and Margin Expansion
PositiveOn November 4, 2026, Insulet reported third-quarter revenue of $842.0 million, up 19.2% year over year, with Omnipod revenue rising 19.7%. Operating income increased to $189.8 million, net income reached $141.1 million, and adjusted diluted earnings...
Insulet Amends Credit Facilities, Expands Revolving Commitments
PositiveOn September 21, 2026, Insulet Corporation amended its existing credit agreement, replacing $475 million of outstanding term loans with an equal amount of new term loans at lower interest rate margins. The new loans, issued at par, along with cash on...
Insulet Introduces New Executive Deferred Compensation Plan
PositiveOn September 14, 2026, Insulet’s Talent and Compensation Committee approved a Nonqualified Deferred Compensation Plan, effective January 1, 2027, for a select group of management and highly compensated employees under ERISA, including named executive...
Insulet announces upcoming director resignations amid transitions
NeutralOn September 3, 2026, longtime director and former chairman Timothy J. Scannell stepped down from Insulet’s board for health reasons, ending a 12-year tenure that included seven years as chairman during a period of substantial growth and advancement...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
